All In Biotech

Drug Trial Radar · NCT01710631

Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia

A Randomized, Double-Blind, Placebo-Controlled and Open-Label Twelve Month Study of the Safety of (S)-Zopiclone in Adult Subjects With Insomnia

Last checked: Nov 20, 2026Latest source record: Oct 22, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 791 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

791

Actual

Start

Feb 2001

Primary completion

Aug 2002

Study completion Aug 2002

Sponsor

Lead sponsor
Sumitomo Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Oct 19, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A six-month study to determine the safety and efficacy with an additional open-label extension to determine the long-term safety of eszopiclone in the treatment of adult subjects with primary insomnia.

Conditions

  • Primary Insomnia

Interventions

  • eszopiclone 3 mgDrug

    eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).

  • placeboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average sleep latency over the last half of the double-blind study period ("last-three-month average" = mean of the monthly averages for months 4, 5, and 6)Time frame: Months 4-6
  2. Occurrence of Adverse Events (AEs) to evaluate the safety of eszopicloneTime frame: 12 Months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.